Association Between Statin Use and Endometrial Cancer Survival. Issue 1 (July 2015)

• Record Type: Journal Article
• Authors: Nevadunsky, Nicole S.; Van Arsdale, Anne; Strickler, Howard D.; Spoozak, Lori A.; Moadel, Alyson; Kaur, Gurpreet; Girda, Eugenia; Goldberg, Gary L.; Einstein, Mark H.
• Is Part Of: Obstetrics and gynecology. Volume 126:Issue 1(2015)
• Publication Date: 2015-07
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1097/AOG.0000000000000926
• Languages: English
• ISSNs: 0029-7844

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>OBJECTIVE:</title> <p>To evaluate the association of 3 hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor (statin) use and concordant polypharmacy with disease-specific survival from endometrial cancer.</p> </sec> <sec> <title>METHODS:</title> <p>A retrospective cohort study was conducted of 985 endometrial cancer cases treated from January 1999 through December 2009 at a single institution. Disease-specific survival was estimated by Kaplan-Meier analyses. A Cox proportional hazards model was used to study factors associated with survival. All statistical tests were two-sided and performed using Stata.</p> </sec> <sec> <title>RESULTS:</title> <p>At the time of analysis, 230 patients (22% of evaluable patients) died of disease and median follow-up was 3.28 years. Disease-specific survival was greater (179/220 [81%]) for women with endometrial cancer taking statin therapy at the time of diagnosis and staging compared with women not using statins (423/570 [74%]) (log rank test, <italic>P</italic>=.03). This association persisted for the subgroup of patients with nonendometrioid endometrial tumors who were statin users (59/87 [68%]) compared with nonusers (93/193 [43%]) (log rank test, <italic>P</italic>=.02). The relationship remained significant (hazard ratio 0.63, 95% confidence interval [CI] 0.40–0.99) after adjusting for age, clinical stage, radiation, and other factors. Further evaluation of polypharmacy showed an association between concurrent statin and aspirin use with an especially low disease-specific mortality (hazard ratio 0.25, 95% CI 0.09–0.70) relative to those who used neither.</p> </sec> <sec> <title>CONCLUSION:</title> <p>Statin and aspirin use was associated with improved survival from nonendometrioid endometrial cancer.</p> </sec> </abstract>